PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.78%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-14.34%
G&A reduction while AXSM shows 3.35% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
-7.72%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-7.72%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-31.48%
D&A reduction while AXSM shows 2.71% growth. Joel Greenblatt would examine efficiency.
7.65%
EBITDA growth 50-75% of AXSM's 12.03%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
7.72%
Operating income growth 50-75% of AXSM's 12.01%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
158.44%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
12.50%
Similar pre-tax income growth to AXSM's 11.39%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Similar net income growth to AXSM's 11.39%. Walter Schloss would investigate industry trends.
No Data
No Data available this quarter, please select a different quarter.
15.94%
EPS growth 50-75% of AXSM's 26.83%. Martin Whitman would scrutinize operations.
15.94%
Diluted EPS growth 50-75% of AXSM's 26.83%. Martin Whitman would scrutinize operations.
4.10%
Share count reduction exceeding 1.5x AXSM's 20.77%. David Dodd would verify capital allocation.
4.10%
Diluted share reduction exceeding 1.5x AXSM's 20.77%. David Dodd would verify capital allocation.